Mer­ck KGaA inks ADC dis­cov­ery deal with AI tech­bio worth up to $1.4B in mile­stones

Mer­ck KGaA is part­ner­ing with AI tech­bio Caris Dis­cov­ery to iden­ti­fy and de­vel­op new an­ti­body-drug con­ju­gates in a move that could ex­pand the Ger­man com­pa­ny’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER